M
Magnus Vrethem
Researcher at Linköping University
Publications - 120
Citations - 3420
Magnus Vrethem is an academic researcher from Linköping University. The author has contributed to research in topics: Multiple sclerosis & Polyneuropathy. The author has an hindex of 30, co-authored 111 publications receiving 2936 citations.
Papers
More filters
Journal ArticleDOI
Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies.
Gustavo Luna,Peter Alping,Joachim Burman,Katharina Fink,Anna Fogdell-Hahn,Martin Gunnarsson,Jan Hillert,Annette Langer-Gould,Jan Lycke,Petra Nilsson,Jonatan Salzer,Anders Svenningsson,Magnus Vrethem,Tomas Olsson,Fredrik Piehl,Fredrik Piehl,Thomas Frisell +16 more
TL;DR: Patients with MS are at a generally increased risk of infections, and this differs by treatment; among newer treatments, off-label use of rituximab was associated with the highest rate of serious infections.
Journal ArticleDOI
Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab.
Martin Gunnarsson,Clas Malmeström,Markus Axelsson,Peter Sundström,Charlotte Dahle,Magnus Vrethem,Tomas Olsson,Fredrik Piehl,Niklas Norgren,Lars Rosengren,Anders Svenningsson,Jan Lycke +11 more
TL;DR: The effect of natalizumab treatment on the release of 2 brain‐specific tissue damage markers into cerebrospinal fluid (CSF) in MS patients is studied.
Journal ArticleDOI
Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience
Joachim Burman,Ellen Iacobaeus,Anders Svenningsson,Jan Lycke,Martin Gunnarsson,Petra Nilsson,Magnus Vrethem,Sten Fredrikson,C. Martin,Anna Sandstedt,Bertil Uggla,Stig Lenhoff,Jan-Erik Johansson,Cecilia Isaksson,Hans Hägglund,Kristina Carlson,Jan Fagius +16 more
TL;DR: HSCT is a very effective treatment of inflammatory active MS and can be performed with a high degree of safety at experienced centres, and presence of gadolinium-enhancing lesions prior to HSCT was associated with a favourable outcome.
Journal ArticleDOI
A comparison a amitriptyline and maprotiline in the treatment of painful polyneuropathy in diabetics and nondiabetics.
Magnus Vrethem,Jörgen Boivie,Hans J. Arnqvist,Helen Holmgren,Torbjörn Lindström,Lars-Håkan Thorell +5 more
TL;DR: It is concluded that tricyclic antidepressants with a pharmacologic profile similar to amitriptyline are the most effective drugs in the treatment of polyneuropathy pain in both diabetic and nondiabetic patients.
Journal ArticleDOI
Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid
TL;DR: This is the first study to show that natalizumab treatment is associated with a global decline in cytokine and chemokine levels at a protein level, and this finding was most pronounced in CSF, in line with the reduced transmigration of cells into CNS, whereas reduction in plasma levels indicates other possible mechanisms of natalizer treatment.